骨代谢指标在老年骨质疏松性骨折后变化的临床应用

目的 通过测定老年骨质疏松患者骨折后骨代谢生化指标,揭示骨代谢指标在老年骨折患者中的变化规律,提供早期控制老年骨质疏松性骨折后骨吸收的依据,有利于加强骨形成的能力,缩短骨折愈合时间,防止再次骨折及并发症的发生.方法 对82例(男33例,女49例)60岁以上髋部骨折及椎体压缩骨折患者和61例(男29例,女32例)老年健康对照组进行血清骨特异性碱性磷酸酶(Serum Bone Alkaline Phosphates,BALP)、骨钙素(bone gla-containing protein BGP)和血清抗洒石酸酸性磷酸酶5b(tart rate-resistant acid phosphates isoform-5b)测定.结果 (1)老年骨质疏松性骨折患者中TRACP-5b水平明显高于对照组(P<0.001),且女性骨转换高于男性;老年骨质疏松骨折患者BALP水平高于正常组(P<0.01).(2)骨折后骨转换指标(BAP,TRACP-5b)与骨密度呈负相关.结论 骨折后患者骨吸收增加,女性骨转换高于男性,女件骨折后更加重骨质疏松,不利于骨折后愈合,而骨折后监测骨代谢指标,提供早期控制骨吸收的依据,女性更应长期监测骨代谢并抗骨吸收治疗,利于加强骨形成的能力,缩短患者卧床时间,防止再次骨折及并发症.     

血清镁浓度与绝经后骨质疏松症患者骨转换指标和骨密度的相关性研究

目的确定绝经后骨质疏松骨密度(bone mineral density,BMD)和血清骨代谢标志物(bone turnover marker,BTM)酒石酸抗性酸性磷酸酶-5b(tartrate-resistant acid phosphatase-5b,TRAP-5b)、骨特异性碱性磷酸酶(bone-specific alkaline phosphatase,BSAP)、雌二醇(E_2)和镁(Mg~(2+))离子浓度的相关性。方法选取123例绝经后骨质疏松症妇女和97名无骨质疏松症的健康绝经后妇女作为研究对象。采用双能X射线吸收测量扫描评估不同骨骼部位的BMD。通过酶联免疫吸附测定法测量E_2、BSAP和TRAP-5b的血清水平。使用比色光谱技术测定血清Mg~(2+)水平。结果骨质疏松女性血清BTM水平显著高于对照组。BSAP具有中等敏感性(76. 8%)和特异性(84. 7%)(截止点为21. 27 U/L)。在3. 46 U/L的截止点,TRAP-5b的灵敏度为86. 8%,特异性为90. 8%。骨质疏松症患者血清Mg~(2+)浓度显著低于对照组。Mg~(2+)水平与BMD值呈正相关。此外,Mg~(2+)浓度与E_2水平呈正相关。脊柱骨密度与BSAP水平呈负相关。结论本研究表明,BMD与BTM呈负相关,与E_2和Mg~(2+)呈正相关。     

绝经后妇女骨代谢生化指标与骨密度相关性研究

目的探讨绝经女性骨密度与骨代谢生化指标血清抗酒石酸酸性磷酸酶5b的关系。方法 选取我科2007 -2009年人院的绝经女性115例,采用DPX2L型双能X线骨密度检测仪,测定腰椎 (L2 ~L4)及股骨上端[包括股骨颈（NECK)、华氏三角（Ward)及股骨粗隆（TROCH)]的骨密度 (BMD)值;根据Tscore值将人选者分为骨量正常组（48例)和骨质疏松组（67例）。并选未绝经女性 30例,骨密度检查正常者为对照组,采用酶联免疫法测定各组血清骨特异性碱性磷酸酶（ALP)、血清 骨钙素（BGP)、血清抗酒石酸酸性磷酸酶（TRAP-5b)的浓度,并比较三组骨代谢生化指标的变化,并 对BMD与各项骨代谢指标进行相关性分析。结果绝经女性骨质疏松组各部位BMD值均低于骨量 正常组(P<0. 05);骨质疏松组血中ALP、BGP、TRAP-5b浓度均显著高于骨量正常组（P <0. 05 ),骨 量正常组血清ALP、BGP、TRAP-5b浓度显著高于对照组,差异有统计学意义（P < 0. 05 )。对照组各部 位的骨密度值与骨代谢生化指标无明显相关性（P>0.05),在绝经女性骨质疏松组中,ALP和TRAP- 5b与腰椎（L2 ~L4)及股骨颈部位的BMD有一定的关系,呈负相关（r分别为-0. 248、- 0. 364、- 0.434、-0.386 )。结论绝经女性骨质疏松为高转换型,血清ALP、BGP、TRAP-5b浓度变化可反映 骨代谢活动,绝经女性BMD的降低与骨转换率升高有关。检测代谢指标有助于早期防治骨质疏松症 (OP)。     

补肾益骨方对去卵巢大鼠骨质疏松症治疗作用的研究

目的 探讨中药补肾益骨方对去卵巢大鼠骨质疏松症的治疗作用.方法 运用切除大鼠卵巢方法 建立去卵巢骨质疏松症模型,随机分为空白对照组、模型组、倍美力组、补肾益骨方组.采用双能X线骨密度测定法检测各组实验鼠骨密度(BMD)、骨矿含量(BMC);放射免疫分析法和ELISA法等检测各组实验鼠血清雌二醇(E2)、骨钙素(BGP)、抗酒石酸酸性磷酸酶5b(TRACP5b) 和以及尿脱氧吡啶啉(Dpd).结果 补肾益骨方可明显升高 BMD、BMC,提高血清E2及BGP水平,降低TRACP5b和Dpd含量.结论 补肾益骨方通过调节机体相关内分泌功能,抑制骨吸收,降低骨的转换率,减少骨量丢失,增加骨密度,对骨质疏松症有防治作用.     

老年男性2型糖尿病患者骨密度及骨代谢生化指标的研究

目的：探讨老年男性2型糖尿病患骨密度改变及其机制，以了解2型糖尿病是否易合并骨质疏松及其特点。方法：测定70例老年男性2型糖尿病患及60例年龄、体重指数相匹配的健康对照的骨密度，血清骨钙素（BGP）、抗酒石酸酸性磷酸酶（TRAP）、碱性磷酸酶（ALP）、尿钙（Ca）、尿羟脯氨酸（HOP）、空腹及餐后血糖、糖化血红蛋白（HbA1c）等，两组进行比较。结果：老年男性2型糖尿病患较健康对照组骨密度显降低。BGP浓度显低于对照组（P＜0．001）；TRAP、甲状旁腺素（PTH）、尿钙、HOP显高于对照组（P＜0．05）、糖尿病患BMD与病程、年龄、HbA1C、FBG、PBG呈显负相关，与平均体重指数（BMI)呈正相关。结论：老年男性2型糖尿病患较易患骨质疏松，其骨改变特点是：骨吸收增加，骨形成下降；发病机理主要是血糖升高，钙的排出增多和继发性甲状旁腺功能亢进以及胰岛功能减退。     

成都地区不同年龄城乡妇女维生素D和骨代谢指标及骨密度的状况分析

目的评价成都市不同年龄城乡女性居民血清25-羟基维生素D水平并计算维生素D缺乏和不足的患病率,计算各种骨转换指标的平均值,研究维生素D水平与骨转换指标的关系。方法选择2个城镇社区和2个农村社区,30~90岁健康妇女376例,采用酶联免疫法测定1,25-二羟基维生素D、25-羟基维生素D,化学发光免疫分析法测定骨碱性磷酸酶、胶原C端肽、N端骨钙素、抗酒石酸酸性磷酸酶、甲状旁腺素、1型前胶原氨基,用双能X线吸收仪检测腰椎骨密度。结果 25-羟基维生素D平均值为17.2±0.7 ng/m L,N端骨钙素平均值为7.6±0.3 ng/m L,1型前胶原氨基端肽平均值为59.6±4.2 ng/m L,维生素D不足者患病率为:97.0%,缺乏者患病率为:76.86%。同时,25-羟基维生素D与胶原C端肽、抗酒石酸酸性磷酸酶呈负相关,1,25-二羟基维生素D与骨碱性磷酸酶呈正相关关系。50岁以后骨密度显著下降。结论成都市女性居民在冬季维生素D普遍不足,不良的生活方式及低维生素D的摄人应引起重视。     

血清耐酒石酸酸性磷酸酶5b等骨代谢指标在大鼠去卵巢中晚期的变化

目的观察大鼠去卵巢中晚期血清耐酒石酸酸性磷酸酶5b(TRACP5b)的变化以及探讨其意义。方法7月龄SD大鼠70只,实验开始时随机取10只处死作为基线,其余60只分为去卵巢(OVX)和假手术(Sham)两组。3周各组取10只处死,余下的15周处死。处死前称量体重,分离血清测定耐酒石酸酸性磷酸酶5b和碱性磷酸酶(ALP),取左胫骨分7个区测定各骨密度(BMD)。结果OVX组血清TRACP5b呈下降趋势,3周已低于Sham组,15周降到(1.76±0.74)U/L,显著性低于Sham组(3.01±1.06)U/L(P<0.05)。3周OVX组血清ALP为(8.02±1.54)ng/ml,明显高于Sham组(6.61±0.75)ng/ml(P<0.05),15周两组间的差异消失。3周OVX组体重出现增长,15周明显高于Sham组(P<0.05)。3周OVX组胫骨1区BMD明显低于Sham组(P<0.05),15周OVX组胫骨1和2区的BMD均明显低于Sham组(P<0.05)。OVX组胫骨2、3、4和6区15周BMD较3周有明显增长(P<0.05)。结论TRACP5b的变化提示大鼠去卵巢中晚期破骨细胞数目和活性下降,骨吸收处于低水平。     

复合振动仪治疗骨质疏松对骨代谢影响6个月临床观察

目的观察复合振动仪治疗骨质疏松(osteoporosis,OP)对骨代谢的影响。方法70例骨质疏松志愿者随机分成复合振动组(whole body compound vibration training group)35例和对照组(control group)35例,复合振动组采用自行研制的复合振动仪进行全身振动治疗,振动频率45～55Hz,振动强度0.5～0.8g,30min/次,1次/隔天,连续6个月,对照组不进行任何干预,于试验第0、1、3、6个月分别检测复合振动组和对照组碱性磷酸酶(alkaline phosphatase,ALP)、骨钙素(osteocalcin,OC)、抗酒石酸酸性磷酸酶(tartrate-resistance acid phosphatase,TRAP)、钙磷乘积(calcium-phosphorus product,[Ca]×[P])的变化。结果第3、6个月,ALP、OC、TRAP、[Ca]×[P]的P分别为0.003、0.686;0.768、0.618;0.817、0.855;0.077、0.001。ALP早期呈上升的趋势,到第3个月形成一个峰值,然后呈下降趋势,[Ca]×[P]呈不断上升的趋势,OC、TRAP无明显变化趋势。结论复合振动可促进骨组织钙化、促进钙和磷以骨盐形式沉积于骨组织;连续治疗可能使人体产生耐受,降低复合振动的治疗效应,采取短时、间断的加载方式可能更有利于促进复合振动的成骨效果。     

第二代骨吸收生化标志物——血清抗酒石酸酸性磷酸酶5b的临床研究

目的　对血清TRACP5b作为骨吸收生化标志物进行临床研究。方法　利用BoneTRAP试剂盒 ,对 473例正常及骨质疏松患者血清做TRACP5b检测及分析。结果　男性和女性 ,随年龄的增加 ,特别是男性更年期及女性绝经期后 ,血清TRACP5b水平均不断升高 ,表明骨吸收增强 ;当患有骨质疏松后 ,血清中TRACP5b的水平高于同龄人 ,且男性及女性骨质疏松患者血清TRACP5b水平均高于正常人 ,统计学提示有显著性差异。结论　血清TRACP5b是一个较好的骨吸收监测指标     

阿仑膦酸钠对绝经后骨质疏松症患者骨代谢指标的影响

目的观察抗骨吸收药物双膦酸盐对绝经后骨质疏松症患者骨代谢状态的影响。方法本研究为回顾性研究,共收集在我院骨质疏松门诊数据库中临床资料完整的女性绝经后骨质疏松症患者152例,其中阿仑膦酸钠治疗组93例(A组),每周给予阿仑膦酸钠70 mg,一次口服;未服用阿仑膦酸钠对照组59例(B组)。分别观察治疗前和治疗后3、6、12个月骨转换生化指标:骨特异性碱性磷酸酶(BAP)、抗酒石酸酸性磷酸酶(TRAP-5b)及25羟维生素D(25(OH)VD)的变化。结果 A组患者经阿仑膦酸钠治疗3个月后BAP和TRAP-5b水平分别较治疗前下降30.60%和32.95%(P0.001)治疗6个月时完全降至女性绝经前水平,并一直维持在此水平至治疗后12个月。B组患者治疗前后BAP和TRAP-5b水平差异无统计学意义。结论绝经后骨质疏松症患者骨代谢处于高转换状态,其BAP及TRAP-5b水平较绝经前明显升高;经阿仑膦酸钠治疗3个月后高转换状态可以明显改善,骨转换指标BAP和TRAP-5b水平回落到绝经前水平。     

儿童骨代谢标志物

儿童骨骼处于生长发育阶段,不同年龄阶段骨骼的生长存在不均衡性,且容易受疾病、外界环境、药物等诸多因素的影响,所以建立儿童特异的骨代谢标志物十分重要。骨代谢的检测方法很多,传统的双能X线吸收测定法辐射剂量低,精度及准确度高,且为无创性而被广泛应用于儿童骨骼系统疾病的检测,但其测定的骨密度反映的是一段时间内骨骼的静态状况,不能反映骨组织的动态本质,不能早期反映骨量的丢失,易导致骨质疏松的漏诊及误诊。而骨代谢标志物能反映骨代谢转换的动态情况,能反映骨代谢的早期灵敏变化,其测量可以早期评估骨代谢性疾病及监测治疗效果,联合骨密度检测能更准确地评估骨量的丢失,减少骨质疏松的漏诊及误诊。本文综述儿童骨代谢标志物特点及其意义,儿童参考范围、临床应用及影响因素等。以期早期发现儿童骨量的变化,对儿童骨骼系统疾病做到早发现、早诊断、早治疗,提高患儿骨骼系统疾病的近期及远期预后,进而提高儿童的生活质量。     

Biochemical markers of bone metabolism in infants and children under intravenous corticosteroid therapy

The short-term effects of corticosteroids (CS) administered intravenously (IV) on biochemical parameters of bone metabolism were followed in infants and children. Forty-nine patients from 2 months to 10 years of age, admitted to Pediatrics Department for bronchiolitis, viral-associated wheezing and croup, were treated with IV hydrocortisone or methylprednisolone (10 or 2 mg/Kg/day, respectively) for 3 days. Blood and fasting urine were collected on admission (day 1), 2 days later (day 3) and 12 days after the end of therapy (day 15). Fifty-one children of similar age and gender without respiratory problems or bone diseases were used as controls. On day 3, suppression of the bone formation markers osteocalcin (OC) (P < 0.001) and total alkaline phosphatase (ALP) (P < 0.05) was observed, but not of the bone resorption markers of hydroxyproline, pyridinoline and calcium excretion (UHyp/UCr, UPYD/UCr and UDPD/UCr, UCa/UCr). Significant decreases were indicated in serum phosphate (Pi) and the maximum renal tubular Pi reabsorption (TmP/GFR) compared to basal (P < 0.001). No significant changes were noticed in the circulating levels of calcium (Ca), parathyroid hormone (iPTH), 25OHD, 24,25(OH)₂D, 1,25(OH)₂D, the insulin-like growth factor-I (IGF-I) and its binding protein-3 (IGFBP-3). Two weeks after therapy, the increase of OC to higher than basal (P < 0.01) indicated a probable activation of the osteoblasts. Serum Pi and the TmP/GFR index values that had significantly decreased by day 3 returned to pretreatment levels by day 15. When assessing the effects of the CS in relation to age, no changes were detected in the levels of OC and total ALP in the <12-month-old children, but a fall of OC was observed in the >1-year-old group (P < 0.001). In contrast to the OC, the effects on serum and renal tubular reabsorption of phosphate were similar for both groups. In conclusion, short-term IV administered CS led to significant but reversible inhibition of bone formation markers, especially detectable in the >1-year-old children, without affecting the bone resorption ones. The adverse effects on phosphate metabolism were also significant, but temporal and irrespective of age.     

Biochemical bone markers in nephrotic children

In this study we evaluated the effects of high-dose corticosteroid (CS) therapy and the character of the nephrotic syndrome (NS) itself on bones in patients with normal glomerular filtration rate. We measured serum osteocalcin (OC), alkaline phosphatase (ALP), intact parathyroid hormone (iPTH), 25-hydroxyvitamin D, calcium (Ca), phosphorus (P), and magnesium (Mg) levels, and urinary Ca and protein excretion in nephrotic children during the active phase before (group Ia) and after CS treatment (group Ib). The results were compared with age-matched control subjects. A significant increase in urinary Ca excretion was observed after CS treatment. Serum ALP, OC, and iPTH levels were within normal limits at the time of study entry. However, both serum OC and ALP levels showed a significant decrease after the completion of CS treatment (OC from 13.6±9.2 ng/ml to 6.7±5.2 ng/ml and ALP from 151.8±60.2 U/l to 116±43.8 U/l). 25-Hydroxyvitamin D levels increased to 17.2±8.9 g/l from 9.9±6.9 g/l after CS treatment. The effects of recurrent use of CSs were assessed by dividing nephrotic patients into two subgroups: infrequent relapsers (IFR) and frequent relapsers (FR). The cumulative dose of CS was 28,125 mg/m² for IFR and 105,000 mg/m² for FR. The changes in OC, ALP, and 25-hydroxyvitamin D levels after CS treatment were significantly different between IFR and FR. We conclude that high-dose CS treatment causes a decrease in bone formation, as shown by the changes in OC and ALP levels. 25-Hydroxyvitamin D levels remained lower than control subjects after CS therapy. The higher the cumulative dose of CS used the more marked the changes in biochemical bone markers. The contribution of FR to baseline 25-hydroxyvitamin D levels needs further study.     

Serum markers of bone metabolism show bone loss in hibernating bears

Disuse osteopenia was studied in hibernating black bears (Ursus americanus) using serum markers of bone metabolism. Blood samples were collected from male and female, wild black bears during winter denning and active summer periods. Radioimmunoassays were done to determine serum concentrations of cortisol, the carboxy-terminal cross-linked telopeptide, and the carboxy-terminal propeptide of Type I procollagen, which are markers of bone resorption and formation, respectively. The bone resorption marker was significantly higher during winter hibernation than it was in the active summer months, but the bone formation marker was unchanged, suggesting an imbalance in bone remodeling and a net bone loss during disuse. Serum cortisol was significantly correlated with the bone resorption marker, but not with the bone formation marker. The bone formation marker was four- to fivefold higher in an adolescent and a 17-year-old bear early in the remobilization period compared with the later summer months. These findings raise the possibility that hibernating black bears may minimize bone loss during disuse by maintaining osteoblastic function and have a more efficient compensatory mechanism for recovering immobilization-induced bone loss than that of humans or other animals.     

产后妇女骨量和骨代谢生化指标变化的研究

目的 探讨产后妇女骨量和骨代谢生化指标的变化，同时明确年龄、身高、体重、身体指数和月经复潮时间对骨密度变化的影响。方法 对24名健康产妇（21－35岁）在产后6个月内进行了追踪观察。用双能X线吸收测量仪（DEXA）分别在产后3－5d，4月初和7月初测量了腰椎正、侧位和股骨颈BMD，同时检测了血清骨钙素，ICTP，雌二醇（放射免疫方法）及血钙、磷浓度。20名非产妇的BMD值作为对照。结果 哺乳妇女腰椎正位和股骨颈BMD在产后4月初和7月初比产后3－5d升高显著（P＜0．05），腰椎侧位BMD在产后7月初比产后4月初和产后3－5d明显升高（P＜0．01），产后6个月内腰椎和股骨颈的BMD均升高到非产妇组水平；血清骨钙素在产后4月初和7月初比产后3－5d有明显升高（P＜0．01）,而ICTP却有明显降低（P＜0．01）；血钙在产后3个月内升高明显（P＜0．01），而血磷在产后6个月内无明显变化，但两者都在正常范围；月经复潮时间对骨量增加有负性影响，而年龄、身高、体重及身体指数对骨量变化无明显影响。结论 在产后6个月内哺乳妇女的骨量持续增加，达到非产妇组水平；骨转换增快，骨形成超过骨吸收；产后停经时间的延长不利于产后骨量的增加。     

骨胶原代谢指标在乳腺癌骨转移诊断中的应用

目的 探讨特异性溶骨性骨代谢指标-血Ⅰ型胶原吡啶交联羧基末端肽(serum type Ⅰcollagen carboxyterminal telopeptide,sICTP)、尿Ⅰ型胶原吡啶交联氨基末端肽(urinary nitrogen-terminal cross-linked telopeptides,uNTx)和尿吡啶酚(urinary pyridinoline crosslinks,uPYD)诊断乳腺癌患者骨转移的临床应用价值.方法 应用酶联免疫吸附试验(ELISA),测定72例乳腺癌患者的sICTP、uNTx和uPYD水平,并计算此三项指标诊断骨转移的特异度及灵敏度.以核素全身骨扫描为标准,并以CT、X线、MRI等影像学方法确诊,将72例患者分为骨转移组和无骨转移组两组.比较两组患者三项指标浓度的差别,并根据骨痛程度及骨转移范围分为亚组比较其在不同组间浓度差别.结果 骨转移组患者sICTP、uNTx和uPYD浓度均明显高于无骨转移组(P＜0.05);三项指标之间显著相关(r＞0.5,P＜0.05).sICTP、uNTx和uPYD诊断骨转移的灵敏度分别为80.56%、72.00%与80.56%(P＜0.05),特异度为97.22%、83.33%和80.56%(P＜0.05);各项指标水平在不同骨痛程度及骨转移范围组间差异有统计学意义(P＜0.05);各指标浓度水平升高和发生骨转移有明显相关性.结论 溶骨性骨代谢指标sICTP、uNTx和uPYD浓度的测定对于乳腺癌患者骨转移的诊断具有较高的参考价值,其与骨转移临床表现的关系对肿瘤骨转移的病情判断有一定意义.     

Biochemical markers of bone metabolism in bone marrow edema syndrome of the hip

The aim of this study was to evaluate bone metabolism in patients with bone marrow edema syndrome of the hip. In 37 consecutive patients undergoing core decompression of the femoral head, biochemical markers of bone metabolism were measured in aspirates from cancellous bone and in samples obtained simultaneously from peripheral blood. The diagnosis was made by means of radiographs, magnetic resonance imaging (MRI), and core biopsy specimens. Undecalcified microtome section were available for histopathological evaluation. Bone specific alkaline phosphatase (bone ALP), osteocalcin (OC), procollagen Type I N-terminal propeptide (PINP), and C-terminal cross-linking telopeptide (ICTP) were studied. Mean serum levels of analytes were 13.1 ng/mL (OC), 11.2 ng/mL (bone ALP), 4.7 ng/mL (ICTP), and 38.8 ng/mL (PINP). In samples obtained from cancellous bone, mean concentrations of all markers were elevated significantly. The mean bone to serum ratios for bone ALP and OC were 14.1 (P=0.005) and 4.1 (P=0.002), respectively. For collagen Type I metabolites, bone to serum ratios averaged 16.3 (P=0.001) for ICTP and 9.6 (P=0.001) for PINP. Markers of bone formation correlated with each other in serum as well as in aspirates from cancellous bone. Elevation of all markers in aspirates from cancellous bone pointed at increased bone turnover, which correlated with histopathological findings of irregularly woven bone, osteoid seams, and lining cells. Mean serum concentrations of all markers, however, were not different from healthy individuals and thus did not provide any useful clue in the diagnosis of this disease. The lack of osteonecrotic regions in our specimens, the marked increase of bone turnover in samples obtained from edematous lesions, and the fact that none of the patients developed osteonecrosis of the femoral head so far seem to further support the contention that transient bone marrow edema syndrome of the hip is a distinct clinical entity.     

绝经后女性骨密度与骨代谢生化指标的相关性分析

目的分析绝经后女性骨密度(bone mineral density,BMD)与骨代谢生化指标的相关性。方法选取西南医科大学附属医院2017年1月至2018年12月收治的绝经后女性患者151例。根据骨密度T值将患者分为骨质疏松组(83例)、骨量低下组(47例)和骨量正常组(21例),比较三组患者骨代谢生化指标的差异,并对各项指标与BMD进行相关性分析。结果骨质疏松组甲状旁腺素(PTH)、Ⅰ型前胶原氨基末端前肽(P1NP)、Ⅰ型胶原羧基端肽β特殊序列(β-CTX)显著高于骨量低下组和骨量正常组(P0. 05),骨量低下组显著高于骨量正常组(P0. 05)。骨质疏松组体质量指数(bone mass index,BMI)、25(OH) D_3显著低于骨量低下组和骨量正常组(P0. 05),骨量低下组显著低于骨量正常组(P0. 05)。血钙、血磷、骨钙素(BGP)、血清的骨特异性碱性磷酸酶(BALP)在三组之间比较,差异无明显统计学意义(P0. 05)。Spearman相关分析显示,PTH、P1NP、β-CTX与骨密度呈负相关(r=-0. 538,-0. 520,-0. 462,P 0. 05),25(OH) D_3与骨密度呈正相关(r=0. 517,P0. 05),血钙、血磷、BALP、BGP与骨密度无相关性(P0. 05)。结论血清25(OH) D_3、PTH、P1NP、β-CTX与骨密度存在显著相关性,骨代谢生化指标监测有助于绝经后女性骨质疏松的早期诊断。